文献速递胸部肿瘤放疗放疗物理与技术

非小细胞肺癌放化疗后死亡的多因素风险因素

Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2019-09-20

该研究在145例I-IIIB期非小细胞肺癌(NSCLC)患者中构建并外部验证了根治性放化疗后12和24个月死亡的预测模型,纳入临床与剂量学变量。最佳模型结合GTV、吸烟状态和/或心脏平均剂量(MHD),24个月外部验证AUC为0.61-0.65,校准斜率0.64-0.65,提示肿瘤体积与死亡风险强相关,心脏剂量降低可能对较小肿瘤有意义。

要点

  • 肿瘤体积(GTV)与放化疗后2年内死亡风险强相关。
  • 结合GTV、吸烟和MHD的模型外部验证区分度中等(AUC 0.61-0.65)。
  • 模型可识别可能从MHD降低中获益的患者(PPV=77%,NPV=52%)。

核心结论

  • 肿瘤体积是NSCLC根治性放化疗后2年内死亡风险的主要相关因素。
  • 模型提示降低心脏剂量可能对较小肿瘤患者有意义。
  • 吸烟与生存期呈重要负相关。

研究设计与样本

  • 在145例I-IIIB期NSCLC患者中开发预测模型,采用5折交叉验证。
  • 考虑临床变量(体能状态、年龄、GTV、当前吸烟)和剂量学变量(MLD、MHD)。
  • 在3个外部验证数据集(878例经分布式学习、127例、96例)中评估区分度和校准度。

主要发现

  • 最佳区分模型结合GTV、吸烟和/或MHD,12和24个月自助法AUC分别为0.74(95%CI 0.66-0.78)和0.69(95%CI 0.55-0.74)。
  • 外部验证中24个月死亡GTV-吸烟-MHD模型区分度中等(模型更新前AUC=0.61-0.64,更新后AUC=0.64-0.65)。
  • 该模型较仅GTV模型改善有限(0.01-0.07),校准斜率为0.64-0.65。
  • 模型识别MHD降低可能有用患者的PPV=77%、NPV=52%(60% cut-off)。

关键数值与推荐

  • 12个月死亡最佳模型自助法AUC为0.74(95%CI 0.66-0.78)。
  • 24个月死亡最佳模型自助法AUC为0.69(95%CI 0.55-0.74)。
  • 外部验证24个月模型更新前AUC=0.61-0.64,更新后AUC=0.64-0.65。
  • 校准斜率为0.64-0.65。
  • 60% cut-off下PPV=77%,NPV=52%。

临床怎么用

  • 可将GTV、吸烟状态和MHD纳入死亡风险预测,辅助识别高危患者。
  • 对较小肿瘤患者,考虑优化放疗计划以降低心脏剂量。
  • 关注吸烟状态并将其作为不良预后因素进行管理。

局限性

  • 外部验证中模型区分度仅为中等,较GTV-only模型改善有限。
  • 校准斜率低于1,提示预测概率可能存在一定偏差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: A higher radiation dose to the heart is known to be associated with increased mortality in non-small cell lung cancer (NSCLC) patients. It is however unknown what the contribution of the heart dose is when other risk factors for mortality are also accounted for. MATERIALS AND METHODS: We constructed and externally validated prediction models of mortality after definitive chemoradiotherapy for NSCLC. Models were developed in 145 stage I-IIIB NSCLC patients. Clinical (performance status, age, gross tumour volume (GTV) combining primary tumour and involved lymph nodes, current smoker) and dosimetric (mean lung (MLD) and heart (MHD) dose) variables were considered. Multivariable logistic regression models predicting 12 and 24 month mortality were built in 5-fold cross-validation. Discrimination and calibration was assessed in 3 external validation datasets containing 878 (via distributed learning), 127 and 96 NSCLC patients. RESULTS: The best discriminating prediction models combined GTV, smoker and/or MHD: bootstrapping AUC (95% CI) of 0.74 (0.66-0.78) and 0.69 (0.55-0.74) at 12 and 24 months. At external validation, the 24 month mortality GTV-smoker-MHD model robustly showed moderate discrimination (AUC = 0.61-0.64 before and 0.64-0.65 after model update) with limited 0.01-0.07 improvement over a GTV-only model, and calibration slope (0.64-0.65). This model can identify patients for whom a MHD reduction may be useful (e.g. PPV = 77%, NPV = 52% (60% cut-off)). CONCLUSIONS: Tumour volume is strongly related to mortality risk in the first 2 years after chemoradiotherapy for NSCLC. Modelling indicates that efforts to reduce cardiac dose may be relevant for small tumours and that smoking has an important negative association with survival.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Defraene G, Dankers FJWM, Price G, et al. Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer. Radiother Oncol. 2019. PMID: 31547943. doi:10.1016/j.radonc.2019.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。